Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Xtant Medical Holdings Inc (XTNT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: XTNT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 25.7% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 66.61M USD | Price to earnings Ratio - | 1Y Target Price 1.75 |
Price to earnings Ratio - | 1Y Target Price 1.75 | ||
Volume (30-day avg) 104389 | Beta 0.41 | 52 Weeks Range 0.33 - 1.18 | Updated Date 03/27/2025 |
52 Weeks Range 0.33 - 1.18 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.12 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate -0.02 | Actual -0.0134 |
Profitability
Profit Margin -14.03% | Operating Margin (TTM) -5.97% |
Management Effectiveness
Return on Assets (TTM) -8.1% | Return on Equity (TTM) -34.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 95557531 | Price to Sales(TTM) 0.57 |
Enterprise Value 95557531 | Price to Sales(TTM) 0.57 | ||
Enterprise Value to Revenue 0.81 | Enterprise Value to EBITDA 46.01 | Shares Outstanding 139068000 | Shares Floating 37064381 |
Shares Outstanding 139068000 | Shares Floating 37064381 | ||
Percent Insiders 7.91 | Percent Institutions 69.53 |
Analyst Ratings
Rating 5 | Target Price 2.25 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xtant Medical Holdings Inc
Company Overview
History and Background
Xtant Medical Holdings Inc. (XTNT) was founded in 2000 (originally Bacterin International Holdings, Inc.). The company rebranded to Xtant Medical in 2014. They've focused on developing and commercializing regenerative medicine products and surgical implants for spinal and orthopedic applications. Significant milestones include FDA clearances for various product lines and strategic acquisitions to expand their portfolio.
Core Business Areas
- Biologics: Focuses on the processing and distribution of allograft and xenograft tissue products used in surgical procedures to promote tissue repair and regeneration. This involves sourcing, processing, and distributing bone grafts, demineralized bone matrices (DBM), and other biologics.
- Spinal Implants: Designs, develops, and markets a range of spinal implants and instrumentation used in spinal fusion surgeries to stabilize the spine and promote bone growth.
Leadership and Structure
Sean Browne serves as the Chief Executive Officer. The organizational structure includes departments for research and development, manufacturing, sales and marketing, finance, and regulatory affairs. A board of directors oversees the company's strategic direction.
Top Products and Market Share
Key Offerings
- OsteoSponge: A bone graft substitute used in spinal and orthopedic procedures. While specific market share data is not readily available, it competes with products from Medtronic, Stryker, and NuVasive. Revenue contribution not publicly disclosed.
- X-Span Expandable Interbody Device: An expandable interbody fusion device designed to restore disc height and promote spinal fusion. Market share data is not readily available. Competitors include Globus Medical, Zimmer Biomet, and Medtronic. Revenue contribution not publicly disclosed.
Market Dynamics
Industry Overview
The spinal and orthopedic device market is driven by an aging population, increasing prevalence of spinal disorders, and advancements in surgical techniques. It is a competitive market with major players like Medtronic, Johnson & Johnson (DePuy Synthes), and Stryker.
Positioning
Xtant Medical is a smaller player in the spinal and orthopedic device market, focusing on niche areas and innovative technologies. Their competitive advantage lies in their biologics and proprietary implant designs.
Total Addressable Market (TAM)
The global spinal implants and surgical devices market is projected to reach $12.2 billion by 2028. Xtant Medical is positioned to capture a share of this market through its product offerings and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Proprietary biologics technology
- Innovative spinal implant designs
- Established distribution network
- Focus on regenerative medicine
Weaknesses
- Smaller market capitalization compared to major competitors
- Limited financial resources for R&D and marketing
- Dependence on third-party manufacturers
- History of net losses
Opportunities
- Expanding product portfolio through acquisitions and new product development
- Entering new geographic markets
- Capitalizing on the growing demand for minimally invasive surgical techniques
- Partnering with larger medical device companies
Threats
- Intense competition from established medical device companies
- Pricing pressures from healthcare providers and payers
- Regulatory changes and compliance requirements
- Product liability claims
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
- Stryker (SYK)
- Globus Medical (GMED)
Competitive Landscape
Xtant Medical faces intense competition from larger, well-established companies. Their advantages include innovative products and a focus on regenerative medicine, while their disadvantages include limited financial resources and a smaller market presence.
Major Acquisitions
Hospitable Metals, Inc.
- Year: 2021
- Acquisition Price (USD millions): 6
- Strategic Rationale: Expanded Xtant's portfolio of fixation devices used in spine surgery.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are visible in the company's financial statements and SEC filings.
Future Projections: Future growth projections can be found in analyst reports and company presentations.
Recent Initiatives: Recent strategic initiatives include new product launches, acquisitions, and partnerships.
Summary
Xtant Medical is a smaller player in a competitive market, focusing on regenerative medicine and innovative spinal implants. The company's strengths lie in its proprietary technologies, but it faces challenges due to limited financial resources and intense competition. Xtant needs to capitalize on growth opportunities and address its financial vulnerabilities to strengthen its market position. New product releases are promising for the future, but historical losses still impact their ability to succeed. The company needs to carefully manage financial resources and maintain a focus on innovation and market expansion.
Similar Companies
- MDT
- JNJ
- SYK
- GMED
- NUVA
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance can change over time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xtant Medical Holdings Inc
Exchange NYSE MKT | Headquaters Belgrade, MT, United States | ||
IPO Launch date 2015-10-19 | President, CEO & Director Mr. Sean E. Browne | ||
Sector Healthcare | Industry Medical Devices | Full time employees 217 | Website https://www.xtantmedical.com |
Full time employees 217 | Website https://www.xtantmedical.com | ||
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.